U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 10 results

Status:
US Approved Rx (1996)
First approved in 1983

Class (Stereo):
CHEMICAL (RACEMIC)



Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (1996)
First approved in 1983

Class (Stereo):
CHEMICAL (RACEMIC)



Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...
Status:
US Approved Rx (2022)
First approved in 1974

Class (Stereo):
CHEMICAL (ABSOLUTE)



Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate developed by CytRx for treating relapsed and refractory sarcomas, especially L-sarcomas. Aldoxorubicin is a rationally-engineered cytotoxic which delivers a well-established anti-canc...